Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:

Abstract: The embodiments of the present invention provide a predistortion device, method for predistortion and transmitter/receiver system. The predistortion device comprises a predistortion unit, and the predistortion device further comprises: a signal acquiring unit to process the output signals of a transmitting circuit to obtain distorted signals; a signal coupling unit to couple the distorted signals acquired by the signal acquiring unit to the receiving signals inputted to a receiving circuit; and a signal processing unit to decouple the output signals of the receiving circuit to acquire the distorted signals and the receiving signals. With the embodiments of the present invention, an analog receiving circuit may be reused in a half duplexing system and a full duplexing system, and the requirement on the analog receiving circuit is lowered, thereby reducing the cost.

Abstract: This invention provides compounds of formula I-A or I-B: wherein HY, G1, G2, R2, R12, W1, W2, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Abstract: This invention provides compounds of formula IA-a or IB-a and subsets thereof: wherein Z, HY, R1, R2, G1, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Abstract: This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R1, R2, R3, G1, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Abstract: An embodiment of the invention discloses a power amplification device and method and a method for acquiring a power adjusting coefficient. The power amplification device according to one embodiment of the invention includes: a power control module configured to perform power adjusting on an input signal; a power amplification module configured to perform power amplification on the signal subjected to the power adjusting by the power control module; and a pre-distortion module configured to compensate for nonlinear characteristic of the power amplification module; wherein, said power control module is coupled between said pre-distortion module and said power amplification module in series; alternatively, said pre-distortion module is coupled between said power control module and said power amplification module in series. With the embodiment of the invention, a transmitter can be provided with a spectrum including a low side lobe even upon startup.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: This invention relates to a predistorter, a predistortion method, and a predistortion system. The predistorter comprises a modulus value determining section, for determining a modulus value of an input signal; a base searching section, for searching a predetermined base lookup table in accordance with the modulus value of the input signal, so as to obtain a base lookup table value; an offset searching section, for searching a predetermined offset lookup table in accordance with the modulus value of the input signal, so as to obtain an offset lookup table value; an interpolation factor generating section, for generating an interpolation factor in accordance with the modulus value of the input signal; a multiplying section, for multiplying the offset lookup table value with the interpolation factor; and a summating section, for adding a product obtained by the multiplying section to the base lookup table value, so as to obtain a predistortion value.

Abstract: The present invention relates to an adaptive digital predistortion device and method. The adaptive digital predistortion device comprising: a predistortion unit for predistorting an input signal according to a predistortion parameter stored in a look-up table; a cost function generation unit for generating a cost function; a fixed segment point determination unit for determining a fixed segment point; and an update unit for updating parameters (u1, u2, ka) according to the cost function to update the look-up table based on the updated parameters (u1, u2, ka), wherein ka is an updated adaptive segment point, u1 and u2 are slopes on two sides of the adaptive segment point ka; and for subsequently updating parameters (v1, v2) according to the cost function to update the look-up table based on the updated parameters (v1, v2) and the fixed segment point, wherein v1 and v2 are slopes on two sides of the fixed segment point.

Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:

Abstract: This invention relates to an amplifier device and a predistortion control method. The amplifier device comprises a predistortion unit, a predistortion control unit, and an amplifier unit, of which the predistortion control unit controls the predistortion unit in accordance with a signal fed back from the amplifier unit. The predistortion control method comprises determining power of a left side lobe of two side lobes of a frequency spectrum of the signal fed back from the amplifier unit; determining power of a right side lobe of two side lobes of a frequency spectrum of the signal fed back from the amplifier unit; determining a cost function in accordance with the power of the first and right side lobes, and controlling the predistortion unit in accordance with the cost function.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: A battery cover for connecting to a portable electronic device pivotably via a pivot, includes a front cover, a bottom board connected to the front cover and a metal dome fixed between the front cover and the bottom board. The front cover includes a main body, a slide board, a resilient member and a fixing mat. The main body defines a front end adjacent to the pivot and a rear end opposite to the front end. An opening is disposed on the rear end and a first positioning groove is disposed between the front end and the opening. The slide board includes an operation button exposed out of the opening and is operable for slidably engaging with or disengaging from the portable electronic device. The resilient member is received in the first positioning groove and connecting to the slide board. The fixing mat is configured for fixing the slide board and resilient member on the main body.

Abstract: This invention relates to a predistorter, a predistortion method, and a predistortion system. The predistorter comprises a modulus value determining section, for determining a modulus value of an input signal; a base searching section, for searching a predetermined base lookup table in accordance with the modulus value of the input signal, so as to obtain a base lookup table value; an offset searching section, for searching a predetermined offset lookup table in accordance with the modulus value of the input signal, so as to obtain an offset lookup table value; an interpolation factor generating section, for generating an interpolation factor in accordance with the modulus value of the input signal; a multiplying section, for multiplying the offset lookup table value with the interpolation factor; and a summating section, for adding a product obtained by the multiplying section to the base lookup table value, so as to obtain a predistortion value.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: A battery cover includes an inner assembly and an outer assembly. The inner assembly includes an upper board defining an L-shaped groove, a bottom board screwed connected with the upper board; and a metal dome fixed between the upper board and the bottom board to pass throughout the bottom board for contacting the battery compartment. The outer assembly includes a front cover defining a first opening thereon, a slide button receiving in the first opening and the L-shaped groove of the upper board to slidably move along the L-shaped groove.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.